Spruce Biosciences (SPRB) Free Cash Flow (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Free Cash Flow of -$8.7 million for Q1 2026, up 31.31% year-over-year from -$6.7 million in Q1 2025, and down 236.59% quarter-over-quarter from $6.4 million in Q4 2025.
Spruce Biosciences (SPRB) Free Cash Flow (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Free Cash Flow for 8 consecutive years, with -$8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 31.31% year-over-year to -$8.7 million; the TTM figure through Mar 2026 stood at $37.3 million (up 169.39% YoY), while the FY2025 annual figure was $33.3 million, up 159.5% from the prior year.
- Free Cash Flow eased to -$8.7 million in Q1 2026 per SPRB's latest filing, from $6.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $48.5 million in Q3 2025 and bottomed at -$20.7 million in Q4 2024.
- Historically, Free Cash Flow has averaged -$6.3 million across 5 years, with a median of -$11.1 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 657.25% — and 2025, when it surged 625.37%.
- Spruce Biosciences' Free Cash Flow stood at -$11.7 million in 2022, then grew by 4.51% to -$11.2 million in 2023, then slumped by 84.47% to -$20.7 million in 2024, then surged by 130.95% to $6.4 million in 2025, then tumbled by 236.59% to -$8.7 million in 2026.
- Business Quant data shows SPRB's Free Cash Flow at -$8.7 million in Q1 2026, $6.4 million in Q4 2025, and $48.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 39.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.50 Mn |
| Jun 30, 2026 | 39.50 Mn |
| Mar 31, 2026 | -8.74 Mn |
| Mar 31, 2026 | -8.74 Mn |
| Dec 31, 2025 | 6.40 Mn |
| Dec 31, 2025 | 6.40 Mn |
| Sep 30, 2025 | 48.46 Mn |
| Sep 30, 2025 | 48.46 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Dec 31, 2024 | -20.68 Mn |
| Dec 31, 2024 | -20.68 Mn |
| Sep 30, 2024 | -9.22 Mn |
| Sep 30, 2024 | -9.22 Mn |
| Jun 30, 2024 | -11.11 Mn |
| Jun 30, 2024 | -11.11 Mn |
| Mar 31, 2024 | -14.96 Mn |
| Mar 31, 2024 | -14.96 Mn |